Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Frequently asked questions
What sector does Armata Pharmaceuticals Inc (ARMP) operate in?
Armata Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Armata Pharmaceuticals Inc (ARMP) current stock price?
As of the latest data, Armata Pharmaceuticals Inc stock price is $4.26, with a previous close of $4.18. Armata Pharmaceuticals Inc gained $0.08 in the last trading session, representing a 1.91% increase.
What is Armata Pharmaceuticals Inc (ARMP) current market capitalization?
Armata Pharmaceuticals Inc market cap is approximately 158.40 million.
What is Armata Pharmaceuticals Inc (ARMP) Earnings Per Share (EPS)?
The trailing EPS is -$5.29, and the forward EPS is -$1.45.
What is Armata Pharmaceuticals Inc (ARMP) EBITDA?
Armata Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 81.37 million.
Does Armata Pharmaceuticals Inc (ARMP) pay dividends?
No. Armata Pharmaceuticals Inc does not pay a dividend.
How did Armata Pharmaceuticals Inc (ARMP) perform in its most recent earnings report?
In the last report (June 30, 2026), Armata Pharmaceuticals Inc posted an EPS surprise of 43.75% and a revenue surprise of 497.62%.
What is Armata Pharmaceuticals Inc (ARMP) beta (volatility) score?
Armata Pharmaceuticals Inc has a beta of 1.349, suggesting it is more volatile than the market.
